Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Hydroxychloroquine was granted FDA approval on 18 April 1955.
A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)
- Conditions
- Interventions
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Hospital Israelita Albert Einstein
- Target Recruit Count
- 440
- Registration Number
- NCT04321278
- Locations
- 🇧🇷
Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷Hospital de Urgência e Emergência de Rio Branco, Rio Branco, AC, Brazil
🇧🇷Hospital e Clínica São Roque, Ipiaú, BA, Brazil
The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 700
- Registration Number
- NCT04321616
- Locations
- 🇳🇴
Andreas Barratt-Due, Oslo, Norway
Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)
- Conditions
- Interventions
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 1600
- Registration Number
- NCT04318444
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)
- Conditions
- Interventions
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2022-02-01
- Target Recruit Count
- 289
- Registration Number
- NCT04318015
- Locations
- 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", Mexico, City, Mexico
Hydroxychloroquine in ANCA Vasculitis Evaluation
- Conditions
- Interventions
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Target Recruit Count
- 43
- Registration Number
- NCT04316494
- Locations
- 🇬🇧
Royal Berkshire NHS Foundation Trust, Reading, Berkshire, United Kingdom
🇬🇧Royal United Hospitals Bath NHS Foundation Trust, Bath, Somerset, United Kingdom
🇬🇧University Hospitals Sussex NHS Foundation Trust, Brighton, Sussex, United Kingdom
Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)
- Conditions
- Interventions
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2022-02-01
- Target Recruit Count
- 320
- Registration Number
- NCT04315896
- Locations
- 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", Mexico, City, Mexico
Norwegian Coronavirus Disease 2019 Study
- Conditions
- Interventions
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2020-06-05
- Lead Sponsor
- University Hospital, Akershus
- Target Recruit Count
- 53
- Registration Number
- NCT04316377
- Locations
- 🇳🇴
Akershus University Hospital, Lørenskog, Norway
Trial of Treatments for COVID-19 in Hospitalized Adults
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2023-11-29
- Target Recruit Count
- 1552
- Registration Number
- NCT04315948
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Martinique, Fort De France, France
🇫🇷Centre Hospitalier Andrée Rosemon, Cayenne, France
🇫🇷CHU APHP Ambroise-Paré, Boulogne-Billancourt, France
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
- Conditions
- Interventions
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 1312
- Registration Number
- NCT04308668
- Locations
- 🇨🇦
Research Institute of the McGill University Heath Centre, Montréal, Quebec, Canada
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
- Conditions
- Interventions
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 65
- Registration Number
- NCT04307693
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.